Profile picture

Assistant Professor Kevin Alexander

Stanford University School of Medicine, Palo Alto (United States of America)
Membership: ESC Professional Member HFA Member
Follow
Logo ESC

Contributor content

Durable survival benefits of acoramidis over 54 months in variant transthyretin amyloid cardiomyopathy (ATTR-CM), including p.V142I: interim findings from ATTRibute-CM and its open-label extension
Presentation
Durable survival benefits of acoramidis over 54 months in variant transthyretin amyloid cardiomyopathy (ATTR-CM), including p.V142I: interim findings from ATTRibute-CM and its open-label extension
See more
Acoramidis reduces cardiovascular mortality (CVM): results at month 42 from the ATTRibute-CM open-label extension (OLE) study
Presentation
Acoramidis reduces cardiovascular mortality (CVM): results at month 42 from the ATTRibute-CM open-label extension (OLE) study
See more
Treatment patterns and clinical outcomes following diagnosis in patients with ATTR Amyloidosis - Results from the OverTTuRe Study
Presentation
Treatment patterns and clinical outcomes following diagnosis in patients with ATTR Amyloidosis - Results from the OverTTuRe Study
See more
Acoramidis treatment is associated with a lower incidence of atrial fibrillation/atrial flutter events in patients with ATTR-CM: post-hoc analyses of the ATTRibute-CM trial
Presentation
Acoramidis treatment is associated with a lower incidence of atrial fibrillation/atrial flutter events in patients with ATTR-CM: post-hoc analyses of the ATTRibute-CM trial
See more

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources